Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Loncar Cancer Immunotherapy ETF CNCR
$13.38
-$0.49 (-3.64%)
На 18:01, 12 мая 2023
Ключевые показатели
-
Marketcap
0.00000000
-
week52high
18.01
-
week52low
11.68
-
Revenue
-
P/E TTM
0
-
Beta
0.00000000
-
EPS
0.00000000
-
Last Dividend
2.59700000
-
Next Earnings Date
07 мая 2023 г. в 02:08
Описание компании
The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
ALPS' Biotech ETF SBIO Week's Top Performer
ETF Trends
24 апр 2023 г. в 17:48
In a somewhat surprising turn, biotech and life sciences-focused ETFs were the driving themes in the last week's top-performing ETFs, with the ALPS Medical Breakthroughs ETF (SBIO) leading the way with a 10% return.
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
InvestorPlace
15 мар 2023 г. в 11:31
Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.
Can Health Care Stocks Outperform Again In 2023?
Seeking Alpha
11 янв 2023 г. в 18:09
How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.
5 Top-Ranked ETFs to Buy at Bargain Prices for 2023
Zacks Investment Research
04 янв 2023 г. в 12:47
Concerns over higher inflation and rising rates continued to weigh on investors' sentiments. This has provided a compelling opportunity for investors to buy cheap heading into 2023.
5 ETFs Riding High on the Biotech Comeback
Zacks Investment Research
08 июл 2022 г. в 12:25
Biotech, the downtrodden segment of the market, has made a solid comeback on bargain hunting.